期刊
CELL STEM CELL
卷 7, 期 5, 页码 618-630出版社
CELL PRESS
DOI: 10.1016/j.stem.2010.08.012
关键词
-
资金
- Harvard Stem Cell Institute
- A*Star Institute of Medical Biology and Singapore stem cell consortium
- Roberto and Allison Mignone Fund for Stem Cell Research
- Howard Hughes Medical Institute
- NIH [RL1DE019021]
- SysCODE (Systems-based Consortium for Organ Design Engineering)
Clinical application of induced pluripotent stem cells (iPSCs) is limited by the low efficiency of iPSC derivation and the fact that most protocols modify the genome to effect cellular reprogramming. Moreover, safe and effective means of directing the fate of patient-specific iPSCs toward clinically useful cell types are lacking. Here we describe a simple, nonintegrating strategy for reprogramming cell fate based on administration of synthetic mRNA modified to overcome innate antiviral responses. We show that this approach can reprogram multiple human cell types to pluripotency with efficiencies that greatly surpass established protocols. We further show that the same technology can be used to efficiently direct the differentiation of RNA-induced pluripotent stem cells (RiPSCs) into terminally differentiated myogenic cells. This technology represents a safe, efficient strategy for somatic cell reprogramming and directing cell fate that has broad applicability for basic research, disease modeling, and regenerative medicine.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据